Surgical Science Sweden AB

As of June 30, 2026, Surgical Science Sweden AB carries a market capitalization of 196.80M, placing it among publicly traded companies globally. Its enterprise value stands at 129.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Surgical Science Sweden AB's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Surgical Science Sweden AB has 51.03M shares outstanding.

As of June 30, 2026, Surgical Science Sweden AB trades at a trailing price-to-earnings ratio of 20.49. The price-to-sales ratio is 1.87, and the price-to-book ratio stands at 0.42.

As of June 30, 2026, Surgical Science Sweden AB trades at an EV/EBITDA multiple of 10.19 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.19 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Surgical Science Sweden AB trades at an EV/FCF ratio of 15.03, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 129.18M versus a market cap of 196.80M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Surgical Science Sweden AB maintains a current ratio of 4.20, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Surgical Science Sweden AB posted a return on equity (ROE) of 2.10, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.05 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.92, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.10, useful for judging operating efficiency across full business cycles. The company generates approximately 347,782.42 in revenue per employee across its workforce of 303.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.55 indicates how many times Surgical Science Sweden AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Surgical Science Sweden AB recorded 3.40M in income tax expense. That works out to an effective tax rate of 26.11, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 13.00M, leaving 9.61M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 19, 2026, Surgical Science Sweden AB's stock has declined approximately 37.71% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Surgical Science Sweden AB generated 105.47M in revenue and converted that into 9.61M in net income, yielding earnings per share of 0.19. EBITDA reached 12.68M, while operating income came in at 12.68M.

As of June 30, 2026, Surgical Science Sweden AB holds 67.91M in cash and equivalents against 294,684.34 in total debt, resulting in a net debt position of -67.61M. Total book value stands at 469.40M, with working capital of 99.04M providing operational flexibility.

Surgical Science Sweden AB produced 15.38M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -6.79M in capital expenditures, free cash flow totaled 8.59M - equivalent to 0.17 per share.

Over the twelve months ended June 30, 2026, Surgical Science Sweden AB posted a gross margin of 66.50, reflecting its pricing power and cost economics. The operating margin of 12.02 and net profit margin of 9.11 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 4.37, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.48, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Surgical Science Sweden AB shareholders.

Surgical Science Sweden AB's most recent stock split took place on May 25, 2020 with a 1:5 split ratio.

As of June 30, 2026, Surgical Science Sweden AB has an Altman Z-Score of 5.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.